期刊文献+

应用蒙特卡洛模拟优化注射用拉氧头孢钠在新生儿细菌感染性疾病中的初始给药方案 被引量:1

Optimization of Initial Administration Regimens for Latamoxef Sodium for Injection in Neonatal Bacterial Infectious Diseases by Monte Carlo Simulation
下载PDF
导出
摘要 目的:应用蒙特卡罗模拟优化注射用拉氧头孢钠在新生儿细菌感染性疾病中的初始给药方案,为临床合理用药提供参考。方法:参考2017年制定的临床和实验室标准协会标准,明确注射用拉氧头孢钠对敏感菌最低抑菌浓度(MIC)的敏感折点,结合拉氧头孢钠的药品说明书,制定15种不同MIC的初始给药方案,应用群体药物代谢动力学/药物效应动力学模型和蒙特卡洛模拟10000例“真实患者”的获得目标概率(PTA),优化获得最佳的初始给药方案。结果:注射用拉氧头孢钠对敏感菌的敏感折点为MIC≤8μg/mL。当MIC=1μg/mL,所有给药方案PTA>90.0%;当MIC=2μg/mL,除“40 mg/(kg·d)分2次给药,50 mg/(kg·d)分2次给药”方案外,其余给药方案PTA>90.0%;当MIC=4μg/mL,“每天4次所有剂量、80 mg/(kg·d)分3次给药、70 mg/(kg·d)分3次给药、60 mg/(kg·d)分3次给药”共8种给药方案PTA>90.0%;当MIC=8μg/mL,仅“80 mg/(kg·d)分4次给药、70 mg/(kg·d)分4次给药”两种给药方案PTA>90.0%;当4μg/mL≤MIC≤8μg/mL,同一给药剂量下,不同给药频次PTA比较差异有统计学意义;当MIC≤2μg/mL,同一给药剂量下,不同给药频次PTA比较差异无统计学意义。结论:应用蒙特卡洛模拟推荐“60 mg/(kg·d)分2次给药”为注射用拉氧头孢钠在新生儿细菌感染性疾病中的初始给药方案。 Objective:To optimize the initial administration regimens for latamoxef sodium for injection in neonatal bacterial infectious diseases by Monte Carlo simulation,so as to provide reference for rational drug use in clinic.Methods:The sensitive breakpoint of minimal inhibitory concentration(MIC)of latamoxef sodium for injection was determined by referring to the criteria of Clinical and Laboratory Standards Association formulated in 2017.Combined with the drug instructions,15 kinds of initial administration regimens were developed under different MIC.Through the application of population pharmacokinetic/pharmacodynamic model and Monte Carlo simulation of probability of target attainment(PTA)in 10,000 cases of“real patients”,the optimal initial administration regimen was optimized.Results:The sensitive breakpoint of latamoxef sodium for injection to the sensitive bacteria was MIC less than or equal to 8μg/mL.When MIC was 1μg/mL,PTA of all the administration regimens was more than 90%.When MIC was 2μg/mL,PTA of the other administration regimens was more than 90%except for“40 mg/(kg·d)in two doses,50 mg/(kg·d)in two doses”.When MIC was 4μg/mL,PTA of the 8 kinds of administration regimens was more than 90%except for“all doses for 4 times a day,80 mg/(kg·d)in three doses,70 mg/(kg·d)in three doses,60 mg/(kg·d)in three doses”.When MIC was 8μg/mL,PTA of the 2 kinds of administration regimens was more than 90%with“80 mg/(kg·d)in 4 doses,70 mg/(kg·d)in four doses”.When MIC was more than or equal to 4μg/mL and less than or equal to 8μg/mL,PTA showed significant difference under the same dose and different administration regimens.When MIC was less than or equal to 2μg/mL,there was no significant difference in PTA under the same dose and different administration regimens.Conclusion:Monte Carlo simulation is used to recommend“60 mg/(kg·d)in two doses”as the initial administration regimen of latamoxef sodium for injection in neonatal bacterial infectious diseases.
作者 寇晨 韩冬 张亚南 高正平 Kou Chen;Han Dong;Zhang Yanan;Gao Zhengping(Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing Maternal and Child Health Care Hospital,Beijing 100026,China)
出处 《儿科药学杂志》 CAS 2022年第6期29-33,共5页 Journal of Pediatric Pharmacy
基金 首都医科大学附属北京妇产医院2017年中青年学科骨干培养专项课题,编号FYCC201715。
关键词 注射用拉氧头孢钠 新生儿 细菌感染性疾病 蒙特卡洛模拟 latamoxef sodium for injection neonates bacterial infectious diseases Monte Carlo simulation
  • 相关文献

参考文献7

二级参考文献50

  • 1张强,李屯,廖工铁,刘定远.NONMEM法:从临床常规化验数据计算群体药动学参数[J].中国医院药学杂志,1994,14(7):330-333. 被引量:10
  • 2姜德春,王丽,卢炜.用NONMEM法建立中国癫痫儿童丙戊酸钠的群体药动学模型[J].中国药学杂志,2007,42(4):291-294. 被引量:25
  • 3于巧亚,王雪涛.临床厌氧菌的研究现状[J].世界最新医学信息文摘,2014,14(21):123-124. 被引量:2
  • 4Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement. Document M100-$24. Wayne, PA: CLSI; 2014. 被引量:1
  • 5Jones RN, Barry AL, Packer RR, et al. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the Cefoperazone- Sulbactam Combination [ J ]. J Clin Microbiol, 1987,25 ( 9 ) :1725-1729. 被引量:1
  • 6Pitout JDD, Laupland KB. Extended-spectrum [3-1actamase- producing Enterobacteriaceae: an emerging public-health conceru [ J]. Lancet Infect Dis, 2008,8 (2) : 159-166. DOI: 10. 1016/ S1473-3099 (08) 7004143. 被引量:1
  • 7Falagas ME, Karageorgopoulos DE. Extended-spectrum beta- lactamase-producing organisms [ J ]. J Hosp Infect, 2009,73 (4) : 345-354. DOI : 10. 1016/j. jhin. 2009.02. 021. 被引量:1
  • 8Pitout JD. Infections with extended-spectrum beta-lactamase- producing Enterobacteriaceae: changing epidemiology and drug treatment choices [ J ]. Drugs, 2010,70 ( 4 ) : 313-333. DOI : 10. 2165/11533040 4300000000-00000. 被引量:1
  • 9Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum[ beta I - lactamase producing escherichia coli: changing epidemiology and clinical impact[ J]. Curr Opin Infect Dis,2010,23 (5) :320-326. DOI : 10. 1097/qco. 0b013e3283398dcl. 被引量:1
  • 10Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bactercmia : implications of extended-spectrum beta-lactamase production in nosoeomial Infections [ J ] Ann Intern Med, 2004, 140 : 26-32. DOI, 10. 7326/00034819-140-1-200401060430008. 被引量:1

共引文献27

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部